Provided by Tiger Trade Technology Pte. Ltd.

Summit Therapeutics PLC

16.91
+0.52003.17%
Post-market: 16.920.0100+0.06%19:58 EDT
Volume:13.06M
Turnover:224.22M
Market Cap:13.49B
PE:-15.13
High:17.72
Open:16.59
Low:16.17
Close:16.39
52wk High:29.23
52wk Low:12.07
Shares:797.75M
Float Shares:152.34M
Volume Ratio:1.41
T/O Rate:8.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1177
EPS(LYR):-1.4439
ROE:-192.50%
ROA:-101.61%
PB:21.41
PE(LYR):-11.71

Loading ...

BRIEF-Summit Therapeutics Announces Proposed Public Offering Of Common Stock

Reuters
·
Jun 10

Summit Therapeutics launches USD 500 million common stock offering

Reuters
·
Jun 10

Summit Therapeutics - Commences $500 Mln Underwritten Public Offering of Common Stock

THOMSON REUTERS
·
Jun 10

Summit Therapeutics - Proceeds to Fund Ivonescimab R&D, Working Capital, and General Corporate Purposes

THOMSON REUTERS
·
Jun 10

Summit Therapeutics files automatic mixed securities shelf

TIPRANKS
·
Jun 10

Summit Therapeutics: Files for Mixed Shelf Offering; Size Not Disclosed - SEC Filing

THOMSON REUTERS
·
Jun 10

Summit Therapeutics (SMMT) Is Down 6.0% After New Ivonescimab ASCO Data - Has The Bull Case Changed?

Simply Wall St.
·
Jun 08

The Era of the One-Size-Fits-All Cancer Drug Is Ending -- Heard on the Street -- WSJ

Dow Jones
·
Jun 06

Summit Therapeutics Co-CEO Robert W. Duggan reports purchase of 100,000 common shares for $1.46 million

Reuters
·
Jun 05

Summit Therapeutics Co-CEO Mahkam Zanganeh acquires $1.46 million in common shares

Reuters
·
Jun 05

Summit Therapeutics COO/CFO Manmeet Soni acquires 50,000 common shares worth $722,250

Reuters
·
Jun 05

Summit Therapeutics to present at Goldman Sachs Global Healthcare Conference

Reuters
·
Jun 05

Stock Track | Summit Therapeutics Soars 5.03% in After-Hours on Positive Lung Cancer Drug Trial Results

Stock Track
·
Jun 02

Assessing Summit Therapeutics (SMMT) Valuation After New Ivonescimab Phase III And Phase II Trial Results

Simply Wall St.
·
Jun 02

Summit Therapeutics Shares Fall 10%, Reversing Premarket Gains

THOMSON REUTERS
·
Jun 01

Stock Track | Summit Therapeutics Plummets 7.41% Intraday Amid Investor Skepticism Over Lung Cancer Drug Data

Stock Track
·
Jun 01

Stock Track | Summit Therapeutics Plunges 5.25% in Pre-Market Amid Investor Skepticism Over Lung Cancer Drug Data

Stock Track
·
Jun 01

An experimental lung-cancer drug could replace Keytruda one day. But investors aren't wowed.

Dow Jones
·
Jun 01

Summit drops as concerns over older patients cloud cancer trial data

Reuters
·
Jun 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (SMMT), Oculis Holding (OCS) and Cogent Biosciences (COGT)

TIPRANKS
·
Jun 01